Head to Head Contrast: Antares Pharma (ATRS) versus LDR Holding Corp (LDRH)
Antares Pharma (NASDAQ: ATRS) and LDR Holding Corp (NASDAQ:LDRH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Volatility & Risk
Antares Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, LDR Holding Corp has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Earnings & Valuation
This table compares Antares Pharma and LDR Holding Corp’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Antares Pharma||$53.10 million||6.51||-$15.90 million||($0.12)||-18.42|
|LDR Holding Corp||N/A||N/A||N/A||($0.71)||-52.08|
LDR Holding Corp has higher revenue, but lower earnings than Antares Pharma. LDR Holding Corp is trading at a lower price-to-earnings ratio than Antares Pharma, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations for Antares Pharma and LDR Holding Corp, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LDR Holding Corp||0||0||0||0||N/A|
Antares Pharma presently has a consensus target price of $3.95, suggesting a potential upside of 78.73%. Given Antares Pharma’s higher possible upside, analysts clearly believe Antares Pharma is more favorable than LDR Holding Corp.
Institutional and Insider Ownership
36.8% of Antares Pharma shares are owned by institutional investors. 11.6% of Antares Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Antares Pharma and LDR Holding Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LDR Holding Corp||-18.02%||-16.37%||-13.65%|
Antares Pharma beats LDR Holding Corp on 7 of the 11 factors compared between the two stocks.
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
About LDR Holding Corp
LDR Holding Corporation is a medical device company. The Company focuses on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is underlined by Mobi-C, a cervical disc replacement device with a mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc. The Company’s traditional fusion products include Easyspine, MC+, ROI, ROI-T, SpineTune and C-Plate.
Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.